AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

HEMOGENYX PHARMACEUTICALS PLC

Director's Dealing Jun 30, 2020

4938_dirs_2020-06-30_fc0e8877-d071-433c-8545-0866ecc7178a.html

Director's Dealing

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 5181R

Hemogenyx Pharmaceuticals PLC

30 June 2020

Hemogenyx Pharmaceuticals plc

(the "Company")

Director/PDMR Shareholding

Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), and his wife, Olena Wright, have  purchased a total of  434,704 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at an average price of 5.76p per share. Following this transaction, Mr Wright has a total beneficial interest in 1,532,109 Ordinary Shares, representing approximately 0.35 per cent of the Company's issued share capital.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Andrew Wright

b)

Position / status

PDMR: Financial Controller and Company Secretary

c)

Initial notification / amendment

Initial notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares of Hemogenyx Pharmaceuticals plc

Identification code GB00BYX3WZ24

b)

Nature of the transaction

Standalone acquisition of shares

c)

Price(s) and volume(s)

Price(s) Volume(s)
£0.056799 90,554

d)

Aggregated information

-      Aggregated volume

-      Price

Price(s) Volume(s)
£5,143.38 90,554

e)

Date of the transaction

2020-06-29

f)

Place of the transaction

London Stock Exchange

XLON

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Olena Wright

b)

Position / status

PCA: Spouse of Andrew Wright (PDMR: Financial Controller and Company Secretary)

c)

Initial notification / amendment

Initial notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares of Hemogenyx Pharmaceuticals plc

Identification code GB00BYX3WZ24

b)

Nature of the transaction

Standalone acquisition of shares

c)

Price(s) and volume(s)

Price(s) Volume(s)
£0.057799 344,150

d)

Aggregated information

-      Aggregated volume

-      Price

Price(s) Volume(s)
£19,891.53 344,150

e)

Date of the transaction

2020-06-29

f)

Place of the transaction

London Stock Exchange

XLON

Enquiries:

Hemogenyx Pharmaceuticals plc hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder [email protected]
Peter Redmond, Director
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Soltan Tagiev
Peterhouse Capital Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow
US Media enquiries
Lowell Goodman Tel: +1 (323) 646-3249 or [email protected]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHKZGFVRGFGGZG

Talk to a Data Expert

Have a question? We'll get back to you promptly.